Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients

被引:0
|
作者
Mirjam Bachler
Christian Niederwanger
Tobias Hell
Judith Höfer
Dominic Gerstmeyr
Bettina Schenk
Benedikt Treml
Dietmar Fries
机构
[1] UMIT - University for Health Sciences,Institute for Sports Medicine, Alpine Medicine and Health Tourism
[2] Medical Informatics and Technology,Department of Pediatrics, Pediatric Intensive Care Unit, Pediatrics I
[3] Medical University of Innsbruck,Department of Mathematics, Faculty of Mathematics, Computer Science and Physics
[4] University of Innsbruck,Department of Anesthesiology and Intensive Care Medicine, AUVA Trauma Centre Salzburg
[5] Academic Teaching Hospital of the Paracelsus Medical University,Department of General and Surgical Critical Care Medicine
[6] Medical University Innsbruck,undefined
来源
Journal of Thrombosis and Thrombolysis | 2019年 / 48卷
关键词
Anticoagulation; FXII deficiency; aPTT; Critically ill patients; Thromboprophylaxis;
D O I
暂无
中图分类号
学科分类号
摘要
FXII deficiency results in spontaneous prolongation of activated partial thromboplastin time (aPTT), which is widely used to monitor thromboprophylaxis. Misinterpretation of spontaneously prolonged aPTT may result in omission of thromboembolic treatment or even unnecessary transfusion of blood products. This retrospective analysis was performed to calculate a threshold level of FXII resulting in aPTT prolongation. 79 critically ill patients with spontaneous prolongation of aPTT were included. A correlation analysis and a ROC curve for aPTT prolongation predicted by FXII level were created to find the FXII threshold level. Prolongation of aPTT was associated with disease severity. A significant inverse proportionality between FXII and aPTT was seen. A ROC curve for aPTT prolongation, predicted by FXII level (AUC 0.85; CI 0.76–0.93), revealed a FXII threshold level of 42.5%. Of our patients 50.6% experienced a FXII deficiency, in 80.0% of whom we found aPTT to be prolonged without a significantly higher bleeding rate. The FXII deficiency was more common in patients with higher SAPS3 scores, septic shock, transfusion of red blood cells and platelet concentrates as well as in patients receiving renal replacement therapy. Patients with a FXII deficiency and prolonged aPTT less often received anticoagulatory therapy although they were more severely ill. The rate of thromboembolic events was higher in these patients although the difference was not statistically significant. Of all patients with spontaneous aPTT prolongation 50.6% had a FXII level of 42.5% or less. Those patients received insufficient thromboembolic prophylaxis.
引用
收藏
页码:466 / 474
页数:8
相关论文
共 50 条
  • [41] Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
    Monteagudo-Vela, Maria
    Bowles, Christopher
    Raj, Binu
    Robinson, Derek
    Simon, Andre
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (02) : 322 - 325
  • [42] Anti-Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support
    Adatya, Sirtaz
    Uriel, Nir
    Yarmohammadi, Hirad
    Holley, Christopher T.
    Feng, Amy
    Roy, Samit S.
    Reding, Mark T.
    John, Ranjit
    Eckman, Peter
    Zantek, Nicole D.
    JACC-HEART FAILURE, 2015, 3 (04) : 314 - 322
  • [43] Variability in international normalized ratio and activated partial thromboplastin time after injury are not explained by coagulation factor deficits
    Stettler, Gregory R.
    Moore, Ernest E.
    Moore, Hunter B.
    Nunns, Geoffrey R.
    Coleman, Julia R.
    Colvis, Arthur
    Ghasabyan, Arsen
    Cohen, Mitchell J.
    Silliman, Christopher C.
    Banerjee, Anirban
    Sauaia, Angela
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2019, 87 (03) : 582 - 589
  • [44] Effect of Pre-analytical Conditions on Prothrombin Time and Partial Activated Thromboplastin Time
    Beatriz, Moutinho
    Beatriz, Pinto
    Rita, Cardoso
    Helena, Alves
    Monica, Botelho
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2019, 20 (04) : 327 - 331
  • [45] Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial
    Aubron, Cecile
    Chapalain, Xavier
    Bailey, Michael
    Board, Jasmin
    Buhr, Heidi
    Cartwright, Bruce
    Dennis, Mark
    Hodgson, Carol
    Forrest, Paul
    Mcilroy, David
    Murphy, Deirdre
    Murray, Lynne
    Pellegrino, Vincent
    Pilcher, David
    Sheldrake, Jayne
    Tran, Huyen
    Vallance, Shirley
    Cooper, D. James
    Mcquilten, Zoe
    CRITICAL CARE EXPLORATIONS, 2023, 5 (11) : E0999
  • [46] Comparison of Anti-Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Patients With Cirrhosis
    Fuentes, Amaris
    Gordon-Burroughs, Sherilyn
    Hall, Jeffrey B.
    Putney, David R.
    Monsour, Howard P., Jr.
    THERAPEUTIC DRUG MONITORING, 2015, 37 (01) : 40 - 44
  • [47] Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art
    Adcock, Dorothy M.
    Moore, Gary W.
    Montalvao, Silmara de Lima
    Kershaw, Geoffrey
    Gosselin, Robert C.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2023, 49 (06) : 571 - 579
  • [48] The Influence of Free Hemoglobin and Bilirubin on Heparin Monitoring by Activated Partial Thromboplastin Time and Anti-Xa Assay
    Kostousov, Vadim
    Nguyen, Kim
    Hundalani, Shilpa G.
    Teruya, Jun
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (11) : 1503 - 1506
  • [49] ABO Blood Type and Response of Activated Partial Thromboplastin Time to Dabigatran in Nonvalvular Atrial Fibrillation Patients
    Suzuki, Shinya
    Otsuka, Takayuki
    Sagara, Koichi
    Semba, Hiroaki
    Kano, Hiroto
    Matsuno, Shunsuke
    Takai, Hideaki
    Kato, Yuko
    Uejima, Tokuhisa
    Oikawa, Yuji
    Nagashima, Kazuyuki
    Kirigaya, Hajime
    Kunihara, Takashi
    Yajima, Junji
    Sawada, Hitoshi
    Aizawa, Tadanori
    Yamashita, Takeshi
    CIRCULATION JOURNAL, 2015, 79 (10) : 2274 - 2277
  • [50] Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time
    Ahn, Hyun-Young
    Jung, Yuju
    Kim, Tae Wan
    Cho, Yang Hyun
    Yang, Jeong Hoon
    Chung, Chi Ryang
    Min, Myung-Sook
    Ko, Ryoung-Eun
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (04) : 383 - 390